Antiphospholipid (aPL) antibodies refer to antibodies associated with the clinical syndrome of vascular thrombosis and/or pregnancy morbidity, termed as aPL syndrome (APS). aPL antibodies include lupus anticoagulants (LA), anticardiolipin (aCL) antibodies and anti-β2-glycoprotein 1 (anti-β2GP1). aCL antibody is more sensitive than LA and anti-β2GP1 even though the latter are more specific for APS. Interpretation of aPL results should be done collectively together with the clinical presentation of each individual. The latest recommendations and consensus on aPL antibody testings should be closely adhered to by laboratories in order to achieve an accepted standard and to ensure accuracy of test results.
INtrODUctION
aPL Syndrome (APS) is a thrombophilic disorder characterised by arterial and/or venous thrombosis and/or pregnancy morbidity, associated with the presence of a heterogenous group of antibodies called aPL. aPL antibodies are heterogenous groups of antibodies directed against phospholipid (PL)binding proteins. aPL antibodies include LA, aCL antibodies, and anti-β2GP1. The current classification criteria for APS mandate that the presence of at least one of these antibodies is necessary in making the diagnosis of APS. 1 APS is present if at least one clinical criteria and one laboratory criteria are met.
cLASSIFIcAtION crItErIA FOr APS
Clinical Criteria 1. Vascular thrombosis: one or more clinical episodes of arterial, venous, or small vessel thrombosis in any tissue or organ, confirmed by an objective validated criteria such as imaging studies and histopathology.
2. Pregnancy morbidity: one or more unexplained deaths of a morphologically normal foetus at or beyond 10 weeks of gestation, one or more premature births of a morphologically normal neonate before 34 th week of gestation because of eclampsia/severe pre-eclampsia or placental insufficiency, or three or more unexplained consecutive spontaneous abortions before 10 weeks of gestation. 
Laboratory

LUPUS ANtIcOAGULANt
To date, there are no specific tests for LA. LA testing remains complex. LA is detected indirectly by using PL-dependent tests that must fulfill a set of diagnostic criteria set by the International Society of Thrombosis and Haemostasis (ISTH). Lack of uniformity of LA testing and variable application of the ISTH criteria, leading to false negative and false positive results, has been a foremost concern over the past decade. This issue is addressed in the latest recommended guidelines for LA testing published in 2009 2 .
WHY DO WE tESt FOr LA?
LA is the most specific assay for APS though not as sensitive as aCL ELISA. The presence of LA has the strongest association with thromboembolism risk 3 and foetal loss 4 
WHO SHOULD UNDErGO LA tEStING? 2 1. Patient with a Significant Probability of Having APS
In order to minimise false positive results, it has been recommended that the appropriateness of LA testing can be decided using the grading of clinical characteristics as follows: a. Low: venous thromboembolism (VTE) or arterial thromboembolism (ATE) in elderly patients. b. Moderate: incidental finding of prolonged aPTT in asymptomatic individuals, recurrent spontaneous early pregnancy loss, provoked VTE in young patients. c. High: unprovoked VTE and unexplained arterial thrombosis in young patients (<50-years-old), late pregnancy loss, thrombosis at unusual sites, or any thrombosis or pregnancy morbidity in patients with autoimmune disease (eg. systemic lupus erythematosus, autoimmune haemolytic anaemia).
Patient with Unexplained Prolonged aPTT
For those with positive LA, it is compulsory to repeat the test more than 12 weeks after the first test.
SAMPLE AND tESt PrEPArAtION
Blood collection is preferably done before the initiation of any anticoagulant drugs or a sufficient period after their discontinuation. Fresh venous blood is collected in a sodium citrate tube. The sample subsequently undergoes double centrifugation to ensure the sample is platelet poor, with a residual count <10 x 10 9 /L. This involves the regular centrifugation of blood (2,000g, 15 minutes, room temperature), followed by centrifugation of the supernatant plasma at higher speed (>2,500g, 10 minutes). If the test is postponed, the plasma needs to be rapidly frozen at -70 o C or below. Frozen plasma needs to be thawed at 37 o C.
LA DIAGNOStIc crItErIA
The rationale of using PL-dependent tests in LA testing arises from the fact that these anticoagulants bind to negatively charged PLs combined with specific proteins and this prolongs the coagulation test time.
LA testing consists of three steps in order to maximise its diagnostic yield: a. Screening test The prolongation of the clotting time of one (or more) PL-dependent test(s) beyond the upper limit of the reference interval is the first criteria. There are many PL-dependent tests that can be used for this step, for which dRVVT is the first recommended test and a sensitive aPTT is the second recommended test. These two tests are chosen as they are done based on different principles 2 . This helps in augmenting the diagnostic yield. dRVVT is recommended due to its higher specificity for detecting LA in patients with high risk of thrombosis 6 . dRVVT is also the most robust test in detecting LA 7 . aPTT is used due to its higher sensitivity for LA 8 
cUt-OFF VALUES
Different laboratories use different assays and different instruments, resulting in different cutoff limits. Standardisation in LA testing remains a challenge. Based on the latest guidelines, the cut-off level is defined as the value above the 99 th percentile from the distribution of LA levels in healthy controls 2 . By using the 99 th percentile as cut-off, the specificity of the test will improve. Results are suggestive of LA when their clotting times are longer than the cut-off level. This is applicable to screening and mixing tests.
The use of normalisation ratios (patient sample:pooled normal plasma sample) is the best way to compensate for inter-and intra-assay variation 1 . For example, clotting time ratios (test/control) of >1.1 for dRVTT and >1.2 for KCT are used in many laboratories 9, 10 .
FALSE POSItIVE AND FALSE NEGAtIVE rESULtS
False positive results happen when plasma contains specific antibodies to coagulation factors such as factor VIII or when the plasma has factor deficiencies 11, 12 . The presence of unfractionated heparin may mimic the presence of LA as well, resulting in false positive results 13 . This can be ruled out with prolonged thrombin time, which is normal in the presence of LA. False positive results can be found in elderly patients or if it is the first positive result 14 .
The presence of residual platelets in test plasma, as little as 16 x 10 9 /L, may shorten the coagulation time. This may result in false negative results, especially in those with weak LA 15 . This can be overcome by double centrifugation 16 .
The reagents used to test for syphilis may contain PLs. These can result in a false positive result in those with aPL antibodies. Therefore, aPL antibodies testing may be ordered to help determine the cause of a positive venereal disease research laboratory/ rapid plasma reagin test for syphilis.
SPEcIAL cIrcUMStANcES Patients with Acute Thromboembolic (TE) Events
During an acute TE episode, LA results do not alter the initial management of a patient with acute TE. Nevertheless, most of the coagulation tests used for LA testing can still be done, as they are not affected if the patient is on low molecular weight heparin. If the patient is on unfractionated heparin, LA status is important because aPTT, used to monitor treatment when the patient is on unfractionated heparin, will be affected by LA. Thus, such patients will require alternative laboratory tests for monitoring.
Patients on Vitamin K Antagonist Treatment
LA testing is challenging when a patient is on vitamin K antagonist treatment for thrombosis as vitamin K antagonists mimic the presence of LA. LA testing is important for a patient who has thrombosis but is on vitamin K antagonist treatment, as the persistence of LA is an indication for long-term anticoagulation. Recommended strategies include discontinuation of treatment for one to two weeks before testing, addition of normal pooled plasma into patient's plasma with ratio 1:1 (provided the international normalised ratio is <3) to reverse coagulation defect induced by vitamin K antagonists, and the use of coagulation assays not affected by vitamin K antagonist such as textrarin/ ecarin clotting time ratio. For those who require the discontinuation of vitamin K antagonist for one to two weeks, low molecular weight heparin can be used, as it does not interfere with most of the coagulation assays used in LA testing.
acL AND anti-β2GP1 ANtIbODIES
Presence of aCL and anti-β2GP1 antibodies are indispensable in the diagnosis of APS. The 13 th International Congress on Antiphospholipid Antibodies published the internal consensus guidelines on aCL and anti-β2GP1 testing in 2012 17 .
IgG aCL and anti-β2GP1 have stronger association with clinical features of APS as compared to IgM isotypes [18] [19] [20] . In the latest APS classification criteria, IgA aCL and anti-β2GP1 are not included. However, there are several reports of isolated IgA anti-β2GP1 positivity with APS 21, 22 . Thus, it is now recommended that the IgA isotypes, for both aCL and anti-β2GP1, to be done in cases where IgG and IgM isotypes are negative but APS is still suspected 17 . It is known that most patients positive for IgA anti-β2GP1 are also positive for IgG and/or IgM anti-β2GP1.
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WHY DO WE tESt FOr acL AND ANtI-β2GP1 ANtIbODIES?
The aCL test is more sensitive and the anti-β2GP1 test more specific for APS diagnosis 23, 24 . aCL antibody is positive in more than 80-90% of patients with APS 25 . However, in 3-10% of APS patients, anti-β2GP1 may be the only positive test 26 . Hence, testing for anti-β2GP1 is imperative in patients suspected of APS in whom aCL IgG and IgM and LA testing are negative.
aCL and/or anti-β2GP1 antibody assays should be repeated, if positive, on two or more occasions at at least 12 weeks apart. This is to rule out a transient increase of levels in the setting of viral or other infections.
SAMPLE AND tESt PrEPArAtION
Either serum or plasma can be used for testing. If serum is used, heat inactivation at 56 o C for 30 minutes should be avoided as this may result in false positive IgM aCL results. Non-haemolysed and non-lipaemic samples should be used. If plasma is used, platelet poor samples (<10 x 10 9 /L) are necessary. Serum samples should be stored at 2-8 o C if testing is going to be done within two to three days after collection and at -20 o C or below if longer storage is required.
ASSAY MEtHODS
These antibodies are measured with ELISA tests. aCL ELISA tests are able to detect both anti-β2GP1 antibodies as well as antibodies to other PL binding proteins. The use of aCL kits, which is a complex of cardiolipin plus (bovine or human) β2GP1 as antigen, is recommended. However, for anti-β2GP1 ELISAs, whole molecule β2GP1of human origin should be used. The new consensus outlines reliable standards that need to be adhered to by laboratories to ensure standardisation of their assays and appropriate calibration to safeguard the accuracy of tests. The precision of the ELISA test is further emphasised, and is reassuring when the coefficient of variation is ≤10%.
MEASUrEMENt AND cUt-OFF
aCL antibodies should be measured using GPL/MPL units. One GPL/MPL unit is defined as the cardiolipinbinding activity of 1ug/ml of affinity-purified IgG or IgM aCL antibody. These are further grouped into low-positive, moderate-positive, or high-positive based on the levels. It is recommended that the cutoffs should be determined using a non-parametric percentile method as autoantibody values do not follow a normal distribution. A cut-off based on the 95 th and 99 th percentiles should be used by the manufacturers. The current classification criteria define clinically significant titres of aCL as >40 GPL and >40 MPL, or higher than the 99 th percentile of the reference range obtained within normal subjects 17 . Nevertheless, these GPL or MPL cutoffs can be different from the 99 th percentile value. GPL or MPL cut-offs for low-positive, moderatepositive, and high-positive are not scientifically studied. Budd et al 27 found that the majority of the IgM aCL positive samples in a large population of healthy individuals fell between the 95 th and 99 th percentiles, but these were not considered to be clinically significant. Therefore, Budd et al 27 recommended that range values between the 95 th -99 th percentiles be considered as a "grey" zone is appropriate above the 99 th percentile in order to prevent over-diagnosis of APS.
There is no universal unit of measurement for anti-β2GP1. Laboratories worldwide have been using different units such as ng/ml, ug/ml, or units/ml. Thus, the development of international units for measurement of anti-β2GP1 antibodies is needed.
ADDItIONAL INFOrMAtION Rheumatoid Factor (RF) Interference
The co-existence of medium or high levels of IgG aCL/anti-β2GP1 antibodies and high levels of IgM RF result in false positive IgM aCL/anti-β2GP1 results 28 . This interference appears to be most significant when the IgG aCL antibody level is at least moderately positive. This has resulted in lower clinical specificity of IgM aCL/anti-β2GP1antibodies. This made reporting of IgM RF important when interpreting IgM aCL/anti-β2GP1 results.
cONcLUSION
The LA result should always be interpreted in the context of a full APS profile, which includes aCL and anti-β2GP1 antibodies. The risk of thrombosis is higher if multiple aPL antibodies are present compared to single antibody positivity. However, the current APS classification criteria mandate that the presence of at least one of these antibodies is necessary in making the diagnosis of APS. The aCL antibody is more sensitive than LA and anti-β2GP1 antibodies even though the latter are more specific for APS. Recommendations and consensus statements for testing of these aPL antibodies testing should be closely adhered to by laboratories in order to
